Wolfe Research Weighs on West Pharmaceutical Services Inc (WST) Stock
Key takeaways
- WST stock is up around 14% year-to-date and has gained nearly 50% over the past year.
- On May 31, Wolfe Research initiated coverage of West Pharmaceutical Services Inc (NYSE:WST) stock with an Outperform rating and a price target of $375.
- Based on Wolfe Research’s earnings estimates for West Pharmaceutical Services, the price target represents 40 times projected EPS for 2027.
Wolfe Research Weighs on West Pharmaceutical Services Inc (WST) Stock Neha Gupta Mon, June 8, 2026 at 12:48 AM GMT+7 2 min read WST ^GSPC West Pharmaceutical Services Inc (NYSE:WST) is one of the best stocks to buy according to billionaire Bill Gates. WST stock is up around 14% year-to-date and has gained nearly 50% over the past year. Analysts still see upside potential in the stock.
On May 31, Wolfe Research initiated coverage of West Pharmaceutical Services Inc (NYSE:WST) stock with an Outperform rating and a price target of $375. The brokerage based its decision on the company’s business fundamentals and valuation history.
Based on Wolfe Research’s earnings estimates for West Pharmaceutical Services, the price target represents 40 times projected EPS for 2027. According to the firm, WST stock has typically traded around 40 times earnings over the past 15 years.